Tharimmune, Inc. (NASDAQ:THAR – Get Free Report) passed above its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $2.14 and traded as high as $2.21. Tharimmune shares last traded at $2.16, with a volume of 512,851 shares.
Tharimmune Trading Up 10.8%
The business has a fifty day moving average of $2.14 and a 200-day moving average of $2.97. The company has a market cap of $81.50 million, a PE ratio of -0.54 and a beta of 1.43.
Tharimmune Company Profile
Tharimmune, Inc (NASDAQ:THAR) is a clinical-stage biotechnology company developing therapeutic candidates for immune-mediated and inflammatory diseases. The company focuses on conditions with significant unmet medical needs, including chronic pruritus and other disorders associated with dysregulated immune responses.
Tharimmune’s lead program, TH104, is an investigational buprenorphine-based therapy designed for the treatment of cholestatic pruritus associated with primary biliary cholangitis, a chronic liver disease.
See Also
- Five stocks we like better than Tharimmune
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.
